Induced Pluripotency as Substitute of Somatic Cell Nuclear Transfer? - The Impact of Induced Pluripotent Stem Cells on Drug Discovery and Regenerative Biopharmaceuticals

Rita P. Cervera, Miodrag Stojkovic

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

This chapter aims to introduce current and future uses of human embryonic stem cells (hESC) derived from in vitro fertilized embryos. These and stem cells derived from parthenogenetic and nuclear transfer embryos could be used for cell therapy, as in vitro cell models for drug discovery/screening and for studying early human development and pathogenesis of human diseases. However, development of therapeutic and screening applications and products from hESC is hampered by several barriers. Therefore, gaps in our current understanding of stem cell basic science need to be filled before either application can move forward with confidence for biopharmaceutical development.

Original languageEnglish (US)
Title of host publicationModern Biopharmaceuticals
Subtitle of host publicationRecent Success Stories
PublisherWiley-VCH
Pages39-55
Number of pages17
ISBN (Print)9783527322831
DOIs
StatePublished - Apr 23 2013
Externally publishedYes

Keywords

  • Differentiation
  • Human embryonic stem cells
  • Induced pluripotency
  • Nuclear transfer
  • Signaling pathway
  • Somatic cells

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Access to Document

Fingerprint Dive into the research topics of 'Induced Pluripotency as Substitute of Somatic Cell Nuclear Transfer? - The Impact of Induced Pluripotent Stem Cells on Drug Discovery and Regenerative Biopharmaceuticals'. Together they form a unique fingerprint.

Cite this